1. UNAIDS. Report on the Global AIDS Epidemic. Geneva: Joint United Nations Programme on HIV/AIDS; 2008.
2. UNAIDS. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress Report. Geneva: World Health Organization, UNAIDS; 2007.
3. Hammer S, Havlir D, Klement E, et al. Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public health Approach. Geneva: World Health Organization; 2003.
4. Antiretroviral Therapy For HIV Infection in Adults And Adolescents: Recommendations for a public health approach. Geneva: World Health Organization; 2006.
5. Hardy D, Reynes J, Konourina I, et al. Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Treatment-experienced Patients Infected with CCR5-Tropic HIV-1: 48-Week Combined Analysis of the MOTIVATE Studies. Boston: CROI; 2008.
6. Steigbigel R, Kumar P, Eron J, et al. 48-Week Results from BENCHMRK-2, a Phase III Study of Raltegravir (RAL) in Patients Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1. Boston: CROI; 2008.
7. Egger M. Outcome of ART in Resource-Limited and Industrialized Countries. CROI. LA Conference Center; 2007.
8. Mills EJ, Nachega JB. A wake-up call for global access to salvage HIV drug regimens. Lancet. 2007;370(9603):1885–1887. [PubMed] 9. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Cote d'Ivoire. N Engl J Med. 2006;355(11):1141–1153. [PubMed] 10. Bishai D, Colchero A, Durack DT. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS. 2007;21(10):1333–1340. [PubMed] 11. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GM, Owens DK. Cost-Effectiveness of HIV Monitoring Strategies in Resource-Limited Settings – A Southern African Analysis. Archives of Internal Medicine. 2008;168(17):1910–1918. [PMC free article] [PubMed] 12. Phillips A, Pillay D, Miners AH, Bennett DE, Gilks C, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet. 2008;371(9622):1443–1451. [PubMed] 13. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850–1861. [PubMed] 14. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006;20(10):1391–1399. [PubMed]
15. Walker S, Kityo C, Kaleebu P, et al. Superior Virological Suppression with Nevirapine, Zidovudine, and Lamivudine vs Abacavir, Zidovudine, and Lamivudine without Evidence of Clinical Benefit to 48 Weeks: A Randomized Comparison in Patients with Low CD4 Counts in Africa. Los Angeles: CROI; 2007.
16. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370(9581):49–58. [PubMed] 17. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568):1169–1178. [PubMed] 18. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. New England Journal of Medicine. 2008;358(15):1590–1602. [PMC free article] [PubMed] 19. Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. Journal of acquired immune deficiency syndromes. 2007;45 Suppl 1:S14–S18. [PubMed] 20. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005;293(7):817–829. [PubMed] 21. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17(9):1369–1375. [PubMed] 22. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45(11):1492–1498. [PubMed] 23. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2(4):e112. [PMC free article] [PubMed]
24. Rewari B, Rajasekaran S, Deshpande A, Chan P, Bachani D, Srikantiah P. Evaluating Patients for Second-line ART in India: Confirmation of Virologic Failure Prevents Unnecessary Treatment Switches. Montreal, Canada: CROI; 2009.
25. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antiviral therapy. 2007;12(1):83–88. [PubMed]
26. Kitahata M, SJ G, RD M, Kuritzkes D. Initiating Rather than Deferring Haart at a CD4+ Count Between 351–500 Cells/mm3 is Associated with Improved Survival 2008. Washington, DC: ICAAC/IDSA; 2008.
27. Walensky RP, Wolf L, Wood R, et al. When to Start ART—A Policy Evaluation While Awaiting Trial Results: South Africa. Montreal, Canada: CROI; 2009.
28. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet. 2006;368(9543):1254–1259. [PubMed] 29. Holmes CB, Wood R, Badri M, et al. CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa: Implications for Prophylaxis and Treatment. J Acquir Immune Defic Syndr. 2006;42(4):464–469. [PubMed] 30. Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med. 2006;3(1):e4. [PMC free article] [PubMed] 32. Stevens G, Rekhviashvili N, Scott LE, Gonin R, Stevens W. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. Journal of clinical microbiology. 2005;43(2):857–861. [PMC free article] [PubMed] 33. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 1998;7(8):723–740. [PubMed] 34. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis. 2008;8:89. [PMC free article] [PubMed]
35. Keiser O. IeDEA, ART-LINC. Switching to Second-line ART, and Mortality in Resource-limited Settings: Collaborative Analysis of Treatment Programs in Africa, Asia, and Latin America. Montreal, Canada: CROI; 2009.
36. World Health Report. Reducing Risk, Promoting Healthy Life. Geneva: World Health Organization; 2002.
37. Macroeconomics and health. investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
38. Etiebet M, Gebi U, Shepherd J, et al. Performance of WHO Immunological Criteria for Determining Virological Treatment Failure in Low-resource Settings. Montreal, Canada: CROI; 2009.
39. Boulle A, Orrel C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antiviral therapy. 2007;12(5):753–760. [PubMed]
40. Calmy A. Outcomes of Adults Receiving Second-line ART in Médecins Sans Frontiéres-supported Projects in Resources-Limited Countries. CROI. Los Angeles Conference Center; 2007.
41. de Mendoza C, Valer L, Ribera E, et al. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. HIV clinical trials. 2006;7(4):163–171. [PubMed] 42. Kaufmann GR, Khanna N, Weber R, et al. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. Antiviral therapy. 2004;9(2):263–274. [PubMed] 43. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349(24):2293–2303. [PubMed] 44. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA. 2001;285(9):1155–1163. [PubMed] 45. Srikantiah P, Walusimbi MN, Kayanja HK, et al. Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS. 2007;21(14):1972–1974. [PubMed] 46. Gulick RM, Lalama CM, Ribaudo HJ, et al. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007;21(7):813–823. [PubMed] 47. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359(9323):2059–2064. [PubMed] 48. Badri M, Cleary S, Maartens G, et al. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther. 2006;11(1):63–72. [PubMed] 49. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of internal medicine. 1997;126(12):946–954. [PubMed] 50. Rodríguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296(12):1498–1506. [PubMed] 51. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364(9428):51–62. [PubMed] 52. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. The New England journal of medicine. 2001;344(7):472–480. [PubMed]
53. Munderi P. DART. Safety of Nevirapine Compared to Abacavir on a Background of Zidovudine/Lamivudine as First-line Antiretroviral Therapy: A Randomized Double-blind Trial. Denver, CO: CROI; 2006.
54. Amoroso A. ART-Associated Toxicities Leading to a Switch in Medication: Experience in Uganda, Kenya, and Zambia. Los Angeles: CROI; 2007.
55. Govender V, McIntyre D, Grimwood A, Maartens G. The Costs and Perceived Quality of Care for People Living with HIV/AIDS in the Western Cape Province in South Africa. Bethesda, MD: Partnerships for Health Reform; 2000.
56. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa - a primary data analysis. Cost effectiveness and resource allocation. 2006;4:1–14. [PMC free article] [PubMed] 57. Thomas LS, Manning A, Holmes CB, et al. Comparative Costs of Inpatient Care for HIV-Infected and Uninfected Children and Adults in Soweto, South Africa. J Acquir Immune Defic Syndr. 2007 [PubMed] 58. Medicines Sans Frontiers, Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. 2007. (Accessed at http://www.accessmed-msf.org/.) 59. Zijenah LS, Kadzirange G, Madzime S, et al. Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting. Journal of translational medicine. 2006;4:33–39. [PMC free article] [PubMed] 60. Rouet F, Rouzioux C. HIV-1 viral load testing cost in developing countries: what's new? Expert Rev Mol Diagn. 2007;7(6):703–707. [PubMed] 61. Calmy AA, Ford NN, Hirschel BB, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clinical infectious diseases. 2007;44(1):128–134. [PubMed]